Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
JOURNAL OF HEPATOLOGY. Bd. 77. 2022 S. S10-S10
Erscheinungsjahr: 2022
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Loomba, Rohit (Autor)
Abdelmalek, Manal F. (Autor)
Armstrong, Matthew (Autor)
Jara, Maximilian (Autor)
Kjaer, Mette (Autor)
Krarup, Niels (Autor)
Lawitz, Eric (Autor)
Ratziu, Vlad (Autor)
Sanyal, Arun (Autor)
Schattenberg, Joern (Autor)
Newsome, Philip N. (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
